Clinical Trials
9 trialsNCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT04386746 2025-11-17
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03519256 2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2 Terminated
NCT03558503 2022-09-16
OPTIMA II
UroGen Pharma Ltd.
Phase 2 Completed
NCT03719300 2020-08-19
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
Anchiano Therapeutics Israel Ltd.
Phase 2 Terminated
NCT00595088 2019-04-30
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Anchiano Therapeutics Israel Ltd.
Phase 2 Completed
NCT02605863 2018-10-03
Enzalutamide for Bladder Cancer Chemoprevention
University of Rochester
Phase 2 Terminated
NCT01687244 2017-07-24
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
FKD Therapies Oy
Phase 2 Completed
NCT02207608 2015-05-28
Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
University of Rome Tor Vergata
Phase 2 Completed